- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04283617
Reversibility of Brain Glucose Transport and Metabolism in T2DM: an Intervention Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Specific Aim 1: To compare brain glucose transport and metabolism in age, BMI, and HbA1c matched T2DM individuals with either long duration of diabetes or short duration of diabetes using brain 1H MRSI during hyperglycemic clamp
Hypothesis: T2DM individuals with chronic uncontrolled diabetes will have lower brain glucose levels as compared with age, BMI, and HbA1c matched T2DM individuals with shorter duration of diabetes.
Screening visit: Volunteers will be screened at the Yale New Haven Hospital (YNHH) Hospital Research Unit (HRU) or Yale Center for Clinical Investigation (YCCI) Church street Research Unit (CSRU) with a medical history and exam. Blood tests will be collected for A1C, ALT, TSH, Hgb and Creatinine. A urine pregnancy test will be performed on all women of childbearing potential, and women who are pregnant will be excluded.
Continuous Glucose Monitoring (CGM): Participants will wear for 14 days prior to the MRSI scanning sessions a CGM (FreeStyle Libre Pro glucose monitoring system) to continuously monitor their interstitial blood glucose levels. Given that this data is blinded, patients will be informed that it is not a replacement for self-monitoring of blood glucose. Subjects should continue their normal testing routine while wearing the sensor. CGM placement will take place at the HRU or CSRU. Those not already using CGM in their usual care will be trained in its proper use by experienced study staff. Patients already using CGM will be allowed to use their usual CGM, however, they will also be asked to wear a second blinded study sensor. Subjects will be provided with our contact information in the event that they have any questions, concerns or issues related to the CGM. Intense exercise may cause the sensor to loosen due to sweat or movement of the sensor. If the CGM sensor falls off while the subject is wearing it, subjects will be asked to return to the HRU or CSRU so that a new sensor can be re-inserted.
The CGM consists of a sensor that measures glucose levels from the interstitial tissue. The sensor is sterile and comes in an unopened package. It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels. A trained study staff member will insert the CGM wirelike tip under the volunteer's skin with the use of the CGM sensor insertion kit. Each sensor is single use only and disposable. The FreeStyle Libre Pro does not require any calibration, as is the case with other CGM devices. This means that no finger sticks are required for its use.
CGM removal: After 14 days of wearing the CGM, it will be removed by a trained study staff member on the on the same day as the subject's scan. To remove the sensor, the adhesive patch will be gently peeled off from the skin, together with the sensor. Removal of the sensor is a painless procedure. The sensor will be discarded after use.
MRSI scanning and Hyperglycemic Clamp: Participants will arrive at MRRC at 7AM on the morning of the study after an 8 hour overnight fast. A urine pregnancy test will be performed on all women of childbearing potential, and women who are pregnant will be excluded. Following IV placements and baseline blood collection, at ~8 AM all T2DM subjects will receive insulin infusion to keep plasma glucose levels at ~100-110 mg/dl. Once glucose levels are stabilized, the subjects will be transferred into the 4T scanner for the hyperglycemia clamp.
Subjects will lie supine in a 4.0 T whole-body magnet interfaced to a Bruker AVANCE spectrometer (Bruker Instruments) with the head immobilized with foam inserts on top of a radiofrequency probe consisting of a 1H coil, as previously described by our group. A nurse experienced with working in a MRS environment will be with subjects at all times. If patients express discomfort or anxiety and ask to be removed from the scanner, the session will be immediately terminated.
Following the 45-minute baseline scan, subjects will remain in the scanner for continuous scanning during the hyperglycemic clamp. An infusion of 20% dextrose at a variable rate to maintain plasma glucose levels at 220 mg/dL for 2 hours. Glucose infusion rates will be adjusted in response to plasma glucose levels measured every 5-10 minutes. Subjects will be able to take breaks as needed during the 2 hours hyperglycemic clamp and MRS scan. During the clamp study a series of hormones will be obtained including insulin levels, GLP1, leptin and free fatty acids.
Neurocognitive testing: Participants will undergo a panel of cognitive testing to assess working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control (CANTAB Cognitive research software, Cambridge Cognition).
Specific Aim 2: To assess the impact that duration of diabetes has on reversibility of brain glucose transport kinetics as assessed by 1H MRSI scanning before and after a 12-week intervention to improve glycemic control
Hypothesis: Participants with shorter duration of diabetes (<5 years) will have greater magnitude of restoration of brain glucose transport parameters compared to T2DM participants with longer duration of diabetes (>5 years).
Subjects: Subjects from Aim 1 will undergo intensification of their diabetes management for a period of 12-week and at the end of the intervention they will undergo 1H MRSI scanning to measure intracerebral and plasma glucose levels at euglycemia and following 2 hours of hyperglycemia using the clamp technique (target glucose 220 mg/dl) in the occipital region. (Figure 2)
Intensification of insulin regimen/Nutrition visit:
The intensification of the diabetes regimens will be managed by Dr. Sanchez Rangel, a fully trained attending endocrinologist, and will follow the general strategies outlined in the Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. All participants will receive exercise and dietary counseling from Mary Savoye, a nutritionist and registered dietician with extensive experience with working with individuals with diabetes and obesity, and who has worked with Dr. Sanchez Rangel on her current pilot. The weight goal will be to have no more than 5% weight change. Participants will have regular phone and in-person MD and nutritionist communication over the course of the 12-week study. All individuals will be asked to perform SMBG at least 4 times a day (before breakfast, lunch, dinner, and bedtime). The daily SMBG records will be sent to Dr. Sanchez Rangel weekly for review to guide adjustment of insulin regimens. Target blood glucose levels will be between 80-130 mg/dl before meals and between < 180 mg/dl at bedtime. Individuals not at goal glycemic targets will undergo intensification of their regimen. Throughout the study, individuals will be contacted via telephone call, email or through additional clinic visits as deemed necessary for maintenance of glycemic control. All individuals will receive education regarding the detection and proper management of hypoglycemia.
Continuous Glucose Monitoring (CGM): Identical to Aim 1.
MRSI scanning and Hyperglycemic Clamp: Study design will be identical to Aim 1
Neurocognitive testing: Study design will be identical to Aim 1
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Elizabeth Sanchez Rangel, MD
- Phone Number: 1 (203) 785-5455
- Email: elizabeth.sanchezrangel@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale New Haven Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Type 2 Diabetics with HbA1c > 7.5% with short duration of diabetes <5 years or
- Type 2 Diabetics with HbA1c > 7.5% longer duration of diabetes >5 years
Exclusion Criteria:
- Patients treated with incretin-based therapies
- Creatinine > 1.5 mg/dL
- Hgb < 10 mg/dL
- ALT > 3 X ULN
- Untreated thyroid disease
- Uncontrolled hypertension
- Known neurological disorders
- Untreated psychiatric disorders
- Malignancy
- Bleeding disorders
- Smoking
- Current or recent steroid use in last 3 months
- Illicit drug use
- Women: pregnancy, actively seeking pregnancy, or breastfeeding
- Inability to enter MRI/MRS (per standard MRI safety guidelines)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Diabetic with short duration
Type 2 diabetics with HbA1c > 7.5 % with short duration of diabetes < 5 years
|
The intensification of the diabetes regimens will be managed by Dr. Sanchez Rangel, a fully trained attending endocrinologist, The weight goal will be to have no more than 5% weight change.
Participants will have regular phone and in-person MD and nutritionist communication over the course of the 12-week study.
All individuals will be asked to perform SMBG at least 4 times a day (before breakfast, lunch, dinner, and bedtime).
The daily SMBG records will be sent to Dr. Sanchez Rangel weekly for review to guide adjustment of insulin regimens.
Target blood glucose levels will be between 80-130 mg/dl before meals and between < 180 mg/dl at bedtime.
Throughout the study, individuals will be contacted via telephone call, email or through additional clinic visits as deemed necessary for maintenance of glycemic control.
All individuals will receive education regarding the detection and proper management of hypoglycemia.
|
Experimental: Diabetic with long duration
Type 2 diabetics with HbA1c > 7.5 % with short duration of diabetes > 5 years
|
The intensification of the diabetes regimens will be managed by Dr. Sanchez Rangel, a fully trained attending endocrinologist, The weight goal will be to have no more than 5% weight change.
Participants will have regular phone and in-person MD and nutritionist communication over the course of the 12-week study.
All individuals will be asked to perform SMBG at least 4 times a day (before breakfast, lunch, dinner, and bedtime).
The daily SMBG records will be sent to Dr. Sanchez Rangel weekly for review to guide adjustment of insulin regimens.
Target blood glucose levels will be between 80-130 mg/dl before meals and between < 180 mg/dl at bedtime.
Throughout the study, individuals will be contacted via telephone call, email or through additional clinic visits as deemed necessary for maintenance of glycemic control.
All individuals will receive education regarding the detection and proper management of hypoglycemia.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intracerebral concentrations of glucose
Time Frame: Baseline
|
Intracerebral concentrations of glucose across multiple brain locations, including frontal and occipital, as measured by MRSI will be compared following hyperglycemic clamp in uncontrolled T2DM individuals with short duration of diabetes and long duration of diabetes
|
Baseline
|
Intracerebral concentrations of glucose between T2DM patients
Time Frame: 12 Weeks
|
Intracerebral concentrations of glucose will be compared between T2DM patients before and after 12 weeks of intensification of their diabetes management
|
12 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Verbal Recognition Memory (VRM)
Time Frame: Baseline
|
Verbal Recognition Memory assesses verbal memory and new learning.
It measures the ability to encode and subsequently retrieve verbal information, with recall tapping into fronto temporal networks and recognition assessing hippocampal areas.
Administration time: 10 minutes
|
Baseline
|
Verbal Recognition Memory (VRM)
Time Frame: 12 Week
|
Verbal Recognition Memory assesses verbal memory and new learning.
It measures the ability to encode and subsequently retrieve verbal information, with recall tapping into fronto temporal networks and recognition assessing hippocampal areas.
Administration time: 10 minutes
|
12 Week
|
Paired Associates Learning (PAL)
Time Frame: Baseline
|
Paired Associates Learning assesses visual memory and new learning.
Outcome measures include the errors made by the participant, the number of trials required to locate the pattern(s) correctly, memory scores and stages completed.
Administration time: 8 minutes
|
Baseline
|
Paired Associates Learning (PAL)
Time Frame: 12 Week
|
Paired Associates Learning assesses visual memory and new learning.
Outcome measures include the errors made by the participant, the number of trials required to locate the pattern(s) correctly, memory scores and stages completed.
Administration time: 8 minutes
|
12 Week
|
Spatial Working Memory (SWM)
Time Frame: Baseline
|
Spatial Working Memory requires retention and manipulation of visuospatial information.
This self-ordered test has notable executive function demands and provides a measure of strategy as well as working memory errors.
Outcome measures include errors (selecting boxes that have already been found to be empty and revisiting boxes which have already been found to contain a token) and strategy and latency.
Administration time: 4 minutes
|
Baseline
|
Spatial Working Memory (SWM)
Time Frame: 12 Week
|
Spatial Working Memory requires retention and manipulation of visuospatial information.
This self-ordered test has notable executive function demands and provides a measure of strategy as well as working memory errors.
Outcome measures include errors (selecting boxes that have already been found to be empty and revisiting boxes which have already been found to contain a token) and strategy and latency.
Administration time: 4 minutes
|
12 Week
|
Reaction Time (RTI)
Time Frame: Baseline
|
Reaction Time provides assessments of motor and mental response speeds, as well as measures of movement time, reaction time, response accuracy and impulsivity.
Outcome measures are divided into reaction time and movement time for both the simple and five-choice variants.
Administration time: 3 minutes
|
Baseline
|
Reaction Time (RTI)
Time Frame: 12 Week
|
Reaction Time provides assessments of motor and mental response speeds, as well as measures of movement time, reaction time, response accuracy and impulsivity.
Outcome measures are divided into reaction time and movement time for both the simple and five-choice variants.
Administration time: 3 minutes
|
12 Week
|
Pattern Recognition Memory (PRM)
Time Frame: Baseline
|
Pattern Recognition Memory is a test of visual pattern recognition memory in a 2-choice forced discrimination paradigm.Outcome measures include the number and percentage of correct trials and latency (speed of participant's response).
Administration time: 4 minutes
|
Baseline
|
Pattern Recognition Memory (PRM)
Time Frame: 12 Week
|
Pattern Recognition Memory is a test of visual pattern recognition memory in a 2-choice forced discrimination paradigm.Outcome measures include the number and percentage of correct trials and latency (speed of participant's response).
Administration time: 4 minutes
|
12 Week
|
Delayed Matching to Sample (DMS)
Time Frame: Baseline
|
Delayed Matching to Sample assesses both simultaneous visual matching ability and short-term visual recognition memory, for non-verbalizable patterns.
Outcome measures include latency (the participant's speed of response), the number of correct patterns selected and a statistical measure giving the probability of an error after a correct or incorrect response.
Administration time: 7 minutes
|
Baseline
|
Delayed Matching to Sample (DMS)
Time Frame: 12 Week
|
Delayed Matching to Sample assesses both simultaneous visual matching ability and short-term visual recognition memory, for non-verbalizable patterns.
Outcome measures include latency (the participant's speed of response), the number of correct patterns selected and a statistical measure giving the probability of an error after a correct or incorrect response.
Administration time: 7 minutes
|
12 Week
|
Rapid Visual Information Processing (RVP)
Time Frame: Baseline
|
Rapid Visual Information Processing is a measure of sustained attention.
Outcome measures cover latency (speed of response), probability of false alarms and sensitivity.
Administration time: 7 minutes
|
Baseline
|
Rapid Visual Information Processing (RVP)
Time Frame: 12 Week
|
Rapid Visual Information Processing is a measure of sustained attention.
Outcome measures cover latency (speed of response), probability of false alarms and sensitivity.
Administration time: 7 minutes
|
12 Week
|
Multitasking Test (MTT)
Time Frame: Baseline
|
The Multitasking Test is a test of the participant's ability to manage conflicting information provided by the direction of an arrow and its location on the screen and to ignore task-irrelevant information.
Outcome measures for the Multitasking Test include response latencies and error scores that reflect the participant's ability to manage multitasking and the interference of incongruent task-irrelevant information on task performance (i.e. a Stroop-like effect).Administration time: 8 minutes
|
Baseline
|
Multitasking Test (MTT)
Time Frame: 12 Week
|
The Multitasking Test is a test of the participant's ability to manage conflicting information provided by the direction of an arrow and its location on the screen and to ignore task-irrelevant information.
Outcome measures for the Multitasking Test include response latencies and error scores that reflect the participant's ability to manage multitasking and the interference of incongruent task-irrelevant information on task performance (i.e. a Stroop-like effect).Administration time: 8 minutes
|
12 Week
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000027293
- 1KL2TR001862-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabete Type 2
-
Hospices Civils de LyonCompletedDiabete Type 2 | Diabete Type 1France
-
Rio Grande do Sul State Health Department - SES/RSAgnes Nogueira Gossenheimer; Ana Paula Rigo; Roberto Eduardo SchneidersNot yet recruitingTelemedicine | Diabete Mellitus | Diabete Type 2 | TelehealthBrazil
-
BiolingusChinese University of Hong KongRecruiting
-
Cliniques universitaires Saint-Luc- Université...Unknown
-
Spaulding Rehabilitation HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsNot yet recruitingAmputation | Diabete Type 2United States
-
National University of SingaporeCompleted
-
Egyptian Chinese UniversityActive, not recruiting
-
University of LiegeEGID, LilleUnknown
-
Assiut UniversityNot yet recruiting
-
Ramsay Générale de SantéEuropean Clinical Trial Experts NetworkRecruitingDiabete Type 2France
Clinical Trials on Intensification of insulin regimen/Nutrition
-
Sun Yat-sen UniversityRecruitingGlucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic DiseaseChina
-
Sante Diabete MaliFrench Development Agency; Société Francophone du Diabète; Centre hospitalo-universiaire...Completed
-
Assaf-Harofeh Medical CenterUnknown
-
M.D. Anderson Cancer CenterWithdrawn
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesUnited States, Puerto Rico, Slovakia, Germany, Argentina, Serbia, Poland, Russian Federation, Slovenia, Spain, Turkey
-
Policlinico HospitalCompletedCritical Ill Patient Undergone Parenteral NutritionItaly
-
Alexandria UniversityRecruitingHemodialysis ComplicationEgypt
-
Sun Yat-sen UniversityNot yet recruitingNewly Diagnosed Type 2 Diabetes | Simplified Short-term Intensive Insulin Therapy | Glycemic RemissionChina
-
University of CambridgeCambridge University Hospitals NHS Foundation TrustCompleted
-
Foundation for Atlanta Veterans Education and Research...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emory... and other collaboratorsRecruitingType 2 DiabetesUnited States